Durable remissions were associated with a high tumor mutation burden, evidence of DNA repair disruption (via BRCA2 mutations and EMSY overexpression), and tumor infiltration of PD‐L1 expressing immune cells. The gene discussed is BRCA2; the disease is neoplasm.